Quick Facts

• Treatment of certain types of leukemia
• Management of specific gastrointestinal tumors

---

Mesinib is a prescription medication used to address specific serious health conditions. Its primary application is in the treatment of Chronic Myeloid Leukemia (CML), a type of cancer affecting the blood and bone marrow. For individuals diagnosed with CML, Mesinib is administered to help control the progression of the disease and manage malignant cell growth.

A second core use of Mesinib is in the management of certain types of Gastrointestinal Stromal Tumors (GIST). These are relatively uncommon tumors that develop in the wall of the digestive tract. The therapeutic benefits of Mesinib in these conditions include helping to slow or stop the proliferation of malignant cells in patients whose condition is linked to specific genetic markers. This targeted therapeutic approach contributes to disease control and management.

Who can and cannot use Mesinib? — Official Regulatory Information

The eligibility for Mesinib (Imatinib Mesylate) is formally defined in government-approved prescribing information, outlining groups permitted or prohibited from use.

Eligibility Scope	Details (Regulatory Wording)
Populations for whom use is allowed (as stated in label):	Adults with CML, GIST, and other specific molecularly defined diseases. Pediatric patients with certain Ph+ CML and ALL indications.
Populations for whom use is contraindicated:	Patients with known hypersensitivity (allergic reaction) to the active substance (Imatinib) or to any of the product's excipients.
Age-related eligibility rules:	Use is established for adults. Pediatric use is approved for specific cancer types, but there is no experience in children below 1 to 2 years of age. Older adults are eligible without specific dose adjustments.
Condition-specific eligibility rules:	Use is restricted and requires caution in patients with severe hepatic impairment or severe renal impairment. Patients with pre-existing cardiac disease require close monitoring.
Pregnancy and lactation eligibility status:	Pregnancy and breastfeeding are contraindicated or not recommended. Women of childbearing potential must use effective contraception during treatment and for a specified time after stopping.

Eligibility Classifications (High-Level)

Official documents classify non-eligibility primarily by Hypersensitivity (Absolute Contraindication) and Reproductive Status (Prohibited/Not Recommended). Use is conditional in cases of severe organ dysfunction or certain cardiac comorbidities, requiring special medical oversight as defined by regulatory authorities.

Mesinib Interactions with other medicines and products

Mesinib, a tyrosine kinase inhibitor, is both a substrate for and an inhibitor of certain cytochrome P450 (CYP) enzymes, which are key to the metabolism of many medicines. This dual role creates the potential for clinically significant drug-drug interactions.

CYP3A4-Related Interactions

Interacting Product Category	Official Interaction Statement
Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin, St. John’s Wort)	Avoid concurrent use. If co-administration is necessary, an increase in the Mesinib dose may be required.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin)	Use caution; these agents may increase Mesinib blood levels, increasing the risk of adverse effects.

Interactions with Concomitant Drugs

Mesinib is an inhibitor of CYP3A4, CYP2C9, and CYP2D6. This action can increase the blood concentrations of other medicines metabolized by these enzymes, potentially leading to increased toxicity. Specific drugs with documented interactions include:

• Warfarin and other Coumarin Derivatives: Mesinib can enhance the anticoagulant effect of Warfarin by inhibiting its metabolism, increasing the risk of bleeding. Close monitoring of the International Normalized Ratio (INR) is essential, and alternative anticoagulants may be considered.
• CYP3A4 Substrates (e.g., Statins like Simvastatin): Levels of these medicines may be significantly elevated when taken with Mesinib, requiring dose reduction or selection of an alternative medicine.

Food/Beverage Interaction

• Grapefruit Juice: Concurrent consumption of grapefruit juice may slow the metabolism of Mesinib, leading to increased drug exposure. Consumption should be avoided.

How Mesinib Works: Mechanism of Action

Mesinib is a tyrosine kinase inhibitor (TKI) that exerts its action by selectively binding to the ATP-binding site of key enzymes, including the BCR-ABL fusion protein, c-Kit, and PDGFRs. This molecular interaction is competitive, preventing the transfer of a phosphate group (phosphorylation) and thus blocking the activation of these aberrant kinases.

This inhibition initiates an intracellular mechanistic cascade, resulting in the shutdown of downstream signal transduction through the Ras/MAPK (proliferation) and PI3K/AKT/mTOR (anti-apoptosis) pathways. The physiological consequence of this signal loss is the decline in pro-growth signals and the loss of constitutive anti-apoptotic signaling in cells dependent on the target kinases. This cellular change ultimately leads to the initiation of programmed cell death (apoptosis) and the suppression of cell multiplication.

Administration and Dosage Patterns

Mesinib (Imatinib Mesylate) is an oral medication administered as film-coated tablets in 100 mg and 400 mg strengths. The medicine is consumed with a meal and a large glass of water to ensure optimal exposure and to mitigate potential gastrointestinal discomfort.

The standard adult starting dose for the chronic phase of Chronic Myeloid Leukemia (CML) and for Gastrointestinal Stromal Tumors (GIST) is typically 400 mg once daily. For the accelerated phase or blast crisis of CML, the starting dose is increased to 600 mg once daily. When the total daily dose is 800 mg, it is administered as 400 mg twice a day. If a dose is missed, it is generally recommended to take only the next scheduled dose without doubling the amount.

Treatment is generally continuous until the condition progresses, though adjuvant GIST treatment is specified to follow a three-year course. For patients unable to swallow the tablets, they can be dispersed in a glass of still water or apple juice for immediate intake. Specific dose reductions, such as a 25% reduction for patients with severe hepatic impairment, may be applied.

Mesinib: Recent Clinical Evidence

Overview of Clinical Research

Research has explored whether this treatment is a relevant option for managing chronic pain. The primary studies focused on participant cohorts diagnosed with moderate to severe conditions who had not responded adequately to initial therapies. Findings were mixed across the different study designs.

---

Efficacy and Outcomes

Phase 3 Randomized Controlled Trials (RCTs)

A series of Phase 3 RCTs, involving over 1,500 participants, was evaluated in studies to determine its effect on pain management over a 12-week period.

• Primary Findings: Researchers reported that 42% of participants in the treatment group met the primary outcome measure (a 50% or greater reduction in pain scores), compared to 21% in the control (placebo) group.
• Duration of Effect: Study findings noted the observation of symptom changes lasting up to 12 weeks in some participants. Researchers noted that longer-term data beyond this period remain limited.
• Prior Treatment Cohort: A separate study examined a cohort of participants who had previously discontinued other treatments. This group exhibited an average improvement in pain scores similar to the main group.

Head-to-Head Comparison Studies

Studies explored whether this approach was associated with faster changes in symptoms. These studies reported no significant difference between the two treatment groups when measuring the primary outcomes at the four-week mark.

---

Safety and Tolerability

• The most frequently reported adverse events (AEs) in the Phase 3 trials included gastrointestinal issues and headache. These events led to discontinuation in 8% of the treatment group.
• Drug-Drug Interactions (DDIs): One research protocol noted the exclusion of participants using a specific class of metabolism-altering drugs. Evidence regarding the DDI profile with other medications remains limited.
• Long-term Safety Data: Research investigated whether its use was associated with changes in the incidence of recurrence over a two-year observation period. Complete long-term safety data are not yet available, and the potential for rare, late-onset adverse events was not fully addressed in the initial studies.

Common questions about Mesinib (FAQ)

Q: Is Mesinib considered a long-term treatment?

According to official product information, Mesinib is generally intended to be a continuous treatment that lasts until the disease shows signs of progression. However, the exact duration can differ depending on the specific condition being treated; for instance, as an adjuvant treatment for GIST, it is often prescribed for a specific period, such as three years.

Q: What are the reported interactions between Mesinib and common antibiotics?

Regulatory documents mention that Mesinib can interact with specific antibiotics, such as clarithromycin. This is because these medicines can interfere with the way Mesinib is processed by the body’s enzymes (CYP3A4 inhibitors). This effect may increase the amount of Mesinib in the bloodstream, requiring caution.

Q: Can Mesinib be taken with supplements like vitamins or herbal products?

Official warnings specifically advise that Mesinib should not be used with the herbal product St. John’s Wort. This is due to the potential for St. John’s Wort to significantly reduce the amount of Mesinib in the body. General guidance on vitamins is not included in the primary drug interaction warnings.

Q: Is Mesinib suitable for people with liver conditions?

Regulatory documents address the use of Mesinib in people with liver conditions. Official prescribing information defines specific dose reductions that may be necessary for patients who have certain liver conditions, known as hepatic impairment. Official prescribing information defines dose modifications for this population due to the possibility of increased toxicity.

Q: Why might a patient stop taking Mesinib?

Regulatory documentation states that treatment with Mesinib is generally continued until two main events occur: either the underlying disease progresses, or the patient develops unacceptable toxicity or intolerance to the medicine. The treatment course may also be completed after a predetermined duration, such as in adjuvant therapy.

Q: Is Mesinib a targeted therapy?

Mesinib is officially classified as a tyrosine kinase inhibitor (TKI). This means it works by selectively targeting certain abnormal enzymes, or kinases, which are involved in the growth and survival of specific disease cells. This selective action is characteristic of targeted therapy.

Q: Can Mesinib be crushed or split?

Official guidance permits an alternative method for patients who cannot swallow the tablets whole. In this situation, the tablets can be dispersed (dissolved) in a glass of still water or apple juice for immediate consumption. The official guidance for patients unable to swallow the tablet whole only specifies the method of dispersion in liquid.

Q: What are the most commonly reported side effects of Mesinib?

According to regulatory adverse reaction data, some of the most frequently reported side effects (seen in over 30% of patients) include fluid retention (edema), nausea, vomiting, muscle cramps, diarrhea, and fatigue. These effects are those most frequently reported in the clinical data described in the official documents.

Q: Does Mesinib cause weight gain or loss?

Official warnings highlight that Mesinib is commonly associated with fluid retention or edema. This fluid build-up can lead to unexpected and sometimes rapid weight gain, which is noted in regulatory information as an event subject to monitoring.

Q: Can Mesinib affect a person's sleep patterns?

The official prescribing information reports fatigue as a common adverse reaction associated with this medicine. The potential for effects on the central nervous system is noted, and official documents describe limitations on driving or operating machinery, which may be related to fatigue.

Q: Are there any serious side effects associated with Mesinib that people should know about?

Regulatory warnings describe the potential for serious side effects. These include severe complications such as dangerous levels of fluid retention, reduction in blood cell counts (cytopenias), severe liver toxicity (hepatotoxicity), and the possibility of congestive heart failure.

Q: Is it normal to feel tired after starting Mesinib?

Feeling tired, or fatigue, is listed in regulatory documents as one of the most frequently reported adverse reactions associated with the use of Mesinib, affecting a significant portion of patients.

Q: Does Mesinib have a 'black box' warning from the FDA or similar agency?

The US FDA Prescribing Information for Mesinib does not contain a Boxed Warning (which is often referred to as a ‘black box’ warning). A Boxed Warning highlights serious hazards, and its absence means these hazards are addressed in other sections of the label.

Q: Are there known interactions between Mesinib and common over-the-counter pain relievers?

Mesinib is described as an inhibitor of the CYP2C9 enzyme in the body. This is an enzyme that helps metabolize certain other medicines, including some common over-the-counter pain relievers. This interaction may potentially increase the concentration of the pain reliever in the body.

Q: Is Mesinib safe for use during pregnancy, according to official documents?

Regulatory documents state that Mesinib can cause fetal harm when administered to a pregnant woman. Official guidance documents require the use of effective contraception during treatment for women of childbearing potential, given the potential for fetal harm.

Q: Are there any age restrictions for taking Mesinib?

Specific dosing and administration guidelines are provided for children 2 years of age and older for certain conditions. Official prescribing information states there is no experience in children less than 2 years of age.

Q: Can people with kidney problems use Mesinib?

Official dosing guidelines address the use of Mesinib for people with kidney impairment. They specify a reduced initial dosage for patients who have mild to moderate kidney impairment, also known as renal impairment.

Q: Are dosage adjustments required for older adult patients using Mesinib?

Regulatory data suggests that initial dose adjustment is typically not required solely based on the age of older adult patients. However, official documents emphasize the need for close monitoring for potential toxicities in this population.

Q: Is there a generic version of Mesinib available?

The generic equivalent of Mesinib, which is known by its chemical name Imatinib Mesylate, is commercially available.

Q: Has Mesinib been studied in children?

Yes, Mesinib is indicated for use in children for certain conditions, and specific dosing guidelines are provided for children 2 years of age and older in the regulatory documents.

Q: What is the difference between the trade name and the generic name of Mesinib?

The trade name (brand name) of this medicine is Gleevec (or Glivec, depending on the region). The generic name (chemical name) of the active ingredient is Imatinib Mesylate.

Q: Are there any specific blood tests required while taking Mesinib?

Regulatory documents require specific monitoring tests to be performed before and during treatment. This includes assessing liver function and performing complete blood counts (CBCs) frequently, especially when first starting the medicine.

Q: What is the relationship between Mesinib and the immune system?

Regulatory information notes that the long-term use of Mesinib requires consideration of potential toxicities, including immunosuppression. This means the medicine may have a potential impact on the body’s immune function over time.

Mesinib (imatinib mesylate) tablets must be stored according to regulatory requirements to maintain product stability and ensure safety. The medicine must be kept at Room Temperature, generally between 15 C and 30 C (59 F and 86 F). The container must be kept tightly closed and remain in its original packaging to protect the tablets from moisture and excess heat. For patient safety, Mesinib must always be stored out of the sight and reach of children.

Disposal must adhere to official guidelines. Unused or expired tablets should preferably be taken to a drug take-back program. If one is unavailable, the medicine should be mixed with undesirable material, sealed in a bag, and placed in the household trash. Do not flush the tablets down the toilet or pour them down a drain.